Bioactive flavonoids and catechols as Hif1 and Nrf2 protein stabilizers - implications for Parkinson's disease

Aging and Disease

Volumn 7, Issue 6, 2016, Pages 745-762

  Smirnova, Natalya A ^a,b   Kaidery, Navneet Ammal ^c   Hushpulian, Dmitry M ^b,d   Rakhman, Ilay I ^a   Poloznikov, Andrey A ^b   Tishkov, Vladimir I ^e   Karuppagounder, Saravanan S ^a   Gaisina, Irina N ^f   Pekcec, Anton ^g,i   Van Leyen, Klaus ^g   Kazakov, Sergey V ^h   Yang, Lichuan ^c,j   Thomas, Bobby ^c   Ratan, Rajiv R ^a   Gazaryan, Irina G ^a,e,h  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b Oncology Inst Moscow Russia   (Russian Federation)

^c MEDICAL COLLEGE OF GEORGIA   (United States)

^d ValentaPharm Ltd   (Russian Federation)

^e MOSCOW STATE UNIVERSITY   (Russian Federation)

^f UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

^h PACE UNIVERSITY   (United States)

ⁱ BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^j Kunming Biomed International ^*  (China)

more..

Author keywords

Fisetin; Glutathione depletion model; HIF prolyl hydroxylase; Keap1; Lipoxygenase; Luteolin; Parkinson's disease model

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3,4 DIHYDROXYBENZOHYDROXAMIC ACID; ARACHIDONIC ACID; CATECHOL; FLAVONOID; GALANGIN; GENTISIC ACID; GLUTATHIONE; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR PROLINE DIOXYGENASE; ISOFLAVONE; KAEMPFEROL; LEVODOPA; NORDIHYDROGUAIARETIC ACID; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; OXIDOREDUCTASE; STABILIZING AGENT; TRANSCRIPTION FACTOR NRF2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOAVAILABILITY; CHELATION; COMPUTER MODEL; CONTROLLED STUDY; EMBRYO; EVOLUTIONARY ADAPTATION; FLUOROMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LUCIFERASE ASSAY; MALE; MOLECULAR DOCKING; MOUSE; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; REAL TIME POLYMERASE CHAIN REACTION; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPECTROPHOTOMETRY; STRUCTURE ACTIVITY RELATION;

EID: 85006515771     PISSN: None     EISSN: 21525250     Source Type: Journal    
DOI: 10.14336/AD.2016.0505     Document Type: Article

References (51)

1. Rossi L, Mazzitelli S, Arciello M, Capo CR, Rotilio G (2008). Benefits from dietary polyphenols for brain aging and Alzheimer's disease. Neurochem Res, 33(12):2390-2400
2. Williams RJ, Spencer JP (2012). Flavonoids, cognition, and dementia: actions, mechanisms, and potential therapeutic utility for Alzheimer disease. Free Radic Biol Med, 52(1):35-45
3. Vauzour D, Vafeiadou K, Rodriguez-Mateos A, Rendeiro C, Spencer JP (2008). The neuroprotective potential of flavonoids: a multiplicity of effects. Genes Nutr, 3(3-4):115-126
4. Hou DX, Kumamoto T (2010). Flavonoids as protein kinase inhibitors for cancer chemoprevention: direct binding and molecular modeling. Antioxid Redox Signal, 13(5):691-719
5. Kuiper GG, Lemmen JG, Carlsson B, Corton JC, Safe SH, van der Saag PT, et al (1998). Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology, 139(10):4252-4263
6. Kaelin WG, Jr (2005). The von Hippel-Lindau protein, HIF hydroxylation, and oxygen sensing. Biochem Biophys Res Commun, 338(1):627-638
7. Dao JH, Kurzeja RJ, Morachis JM, Veith H, Lewis J, Yu V, et al (2009). Kinetic characterization and identification of a novel inhibitor of hypoxia-inducible factor prolyl hydroxylase 2 using a time-resolved fluorescence resonance energy transfer-based assay technology. Anal Biochem, 384(2):213-223
8. Jeon H, Kim H, Choi D, Kim D, Park SY, Kim YJ, et al (2007). Quercetin activates an angiogenic pathway, hypoxia inducible factor (HIF)-1-vascular endothelial growth factor, by inhibiting HIF-prolyl hydroxylase: a structural analysis of quercetin for inhibiting HIF-prolyl hydroxylase. Mol Pharmacol, 71(6):1676-1684
9. Cho H, Lee HY, Ahn DR, Kim SY, Kim S, Lee KB, et al (2008). Baicalein induces functional hypoxia-inducible factor-1alpha and angiogenesis. Mol Pharmacol, 74(1):70-81
10. Deschamps JD, Kenyon VA, Holman TR (2006). Baicalein is a potent in vitro inhibitor against both reticulocyte 15-human and platelet 12-human lipoxygenases. Bioorg Med Chem, 14(12):4295-4301
11. Sekiya K, Okuda H (1982). Selective inhibition of platelet lipoxygenase by baicalein. Biochem Biophys Res Communs, 105(3):1090-1095
12. Slapke J, Schewe T, Hummel S, Winkler J, Kopf M (1983). Lung strips from guinea pigs as test system for lipoxygenase inhibitors. Inhibition of arachidonic acid-induced contractions by 3-t-butyl-4-hydroxyanisole and nordihydroguaiaretic acid. Biomed Biochim Acta, 42(10):1309-1318
13. Vasquez-Martinez Y, Ohri RV, Kenyon V, Holman TR, Sepulveda-Boza S (2007). Structure-activity relationship studies of flavonoids as potent inhibitors of human platelet 12-hLO, reticulocyte 15-hLO-1, and prostate epithelial 15-hLO-2. Bioorg Med Chem, 15(23):7408-7425
14. Schewe T, Halangk W, Hiebsch C, Rapoport SM (1975). A lipoxygenase in rabbit reticulocytes which attacks phospholipids and intact mitochondria. FEBS letters, 60(1):149-52
15. Li Y, Maher P, Schubert D (1997). A role for 12-lipoxygenase in nerve cell death caused by glutathione depletion. Neuron, 19(2):453-463
16. van Leyen K, Siddiq A, Ratan RR, Lo EH (2005). Proteasome inhibition protects HT22 neuronal cells from oxidative glutamate toxicity. J Neurochem, 92(4):824-830
17. van Leyen K, Kim HY, Lee SR, Jin G, Arai K, Lo EH (2006). Baicalein and 12/15-lipoxygenase in the ischemic brain. Stroke, 37(12):3014-3018
18. Khanna S, Roy S, Slivka A, Craft TK, Chaki S, Rink C, et al (2005). Neuroprotective properties of the natural vitamin E alpha-tocotrienol. Stroke, 36(10):2258-2264
19. Yigitkanli K, Pekcec A, Karatas H, Pallast S, Mandeville E, Joshi N, et al (2013). Inhibition of 12/15-lipoxygenase as therapeutic strategy to treat stroke. Ann Neurol, 73(1):129-135
20. Motohashi H, Yamamoto M (2004). Nrf2-Keap1 defines a physiologically important stress response mechanism. Trends Mol Med, 10(11):549-557
21. Itoh K, Wakabayashi N, Katoh Y, Ishii T, Igarashi K, Engel JD, et al (1999). Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev, 13(1):76-86
22. Kobayashi A, Kang MI, Okawa H, Ohtsuji M, Zenke Y, Chiba T, et al (2004). Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol Cell Biol, 24(16):7130-7139
23. Cullinan SB, Gordan JD, Jin J, Harper JW, Diehl JA (2004). The Keap1-BTB protein is an adaptor that bridges Nrf2 to a Cul3-based E3 ligase: oxidative stress sensing by a Cul3-Keap1 ligase. Mol Cell Biol, 24(19):8477-8486
24. Zhang DD, Lo SC, Cross JV, Templeton DJ, Hannink M (2004). Keap1 is a redox-regulated substrate adaptor protein for a Cul3-dependent ubiquitin ligase complex. Mol Cell Biol, 24(24):10941-10953
25. Kaspar JW, Niture SK, Jaiswal AK (2009). Nrf2:INrf2 (Keap1) signaling in oxidative stress. Free Radic Biol Med, 47(9):1304-139
26. Smirnova NA, Rakhman I, Moroz N, Basso M, Payappilly J, Kazakov S, et al (2010). Utilization of an in vivo reporter for high throughput identification of branched small molecule regulators of hypoxic adaptation. Chem & Biol, 17(4):380-391
27. Smirnova NA, Haskew-Layton RE, Basso M, Hushpulian DM, Payappilly JB, Speer RE, et al (2011). Development of Neh2-luciferase reporter and its application for high throughput screening and real-time monitoring of Nrf2 activators. Chem & Biology, 18(6):752-765
28. Dahlstrom M, Forsstrom D, Johannesson M, Huque-Andersson Y, Bjork M, Silfverplatz E, et al (2010). Development of a fluorescent intensity assay amenable for high-throughput screening for determining 15-lipoxygenase activity. J Biomol Screening, 15(6):671-679
29. Semenza GL, Jiang BH, Leung SW, Passantino R, Concordet JP, Maire P, et al (1996). Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. J Biol Chem, 271(51):32529-32537
30. Kaidery NA, Banerjee R, Yang L, Smirnova NA, Hushpulian DM, Liby KT, et al (2013). Targeting Nrf2-mediated gene transcription by extremely potent synthetic triterpenoids attenuate dopaminergic neurotoxicity in the MPTP mouse model of Parkinson's disease. Antiox Redox Signal, 18(2):139-157
31. Nikolic D, van Breemen RB (2004). New metabolic pathways for flavanones catalyzed by rat liver microsomes. Drug metabolism and disposition: the biological fate of chemicals, 32(4):387-397
32. Hirota A, Taki S, Kawaii S, Yano M, Abe N (2000). 1,1-Diphenyl-2-picrylhydrazyl radical-scavenging compounds from soybean miso and antiproliferative activity of isoflavones from soybean miso toward the cancer cell lines. Biosci Biotechnol Biochem, 64(5):1038-1040
33. Rimbach G, De Pascual-Teresa S, Ewins BA, Matsugo S, Uchida Y, Minihane AM, et al (2003). Antioxidant and free radical scavenging activity of isoflavone metabolites. Xenobiotica, 33(9):913-925
34. Rufer CE, Kulling SE (2006). Antioxidant activity of isoflavones and their major metabolites using different in vitro assays. J Agric Food Chem, 54(8):2926-2931
35. Majamaa K, Gunzler V, Hanauske-Abel HM, Myllyla R, Kivirikko KI (1986). Partial identity of the 2-oxoglutarate and ascorbate binding sites of prolyl 4-hydroxylase. J Biol Chem, 261(17):7819-7823
36. Thirstrup K, Christensen S, Moller HA, Ritzen A, Bergstrom AL, Sager TN, et al (2011). Endogenous 2-oxoglutarate levels impact potencies of competitive HIF prolyl hydroxylase inhibitors. Pharmacol Res, 64(3):268-273
37. Krishnamoorthy S, Jin R, Cai Y, Maddipati KR, Nie D, Pages G, et al (2010). 12-Lipoxygenase and the regulation of hypoxia-inducible factor in prostate cancer cells. Exp Cell Res, 316(10):1706-1715
38. Wu Y, Mao F, Zuo X, Moussalli MJ, Elias E, Xu W, et al (2014). 15-LOX-1 suppression of hypoxia-induced metastatic phenotype and HIF-1alpha expression in human colon cancer cells. Cancer Med, 3(3):472-484
39. Siddiq A, Aminova LR, Troy CM, Suh K, Messer Z, Semenza GL, et al (2009). Selective inhibition of hypoxia-inducible factor (HIF) prolyl-hydroxylase 1 mediates neuroprotection against normoxic oxidative death via HIF-and CREB-independent pathways. J Nuerosci, 29(27):8828-8838
40. Maher P (2009). Modulation of multiple pathways involved in the maintenance of neuronal function during aging by fisetin. Genes Nutr, 4(4):297-307
41. Lee-Hilz YY, Boerboom AM, Westphal AH, Berkel WJ, Aarts JM, Rietjens IM (2006). Pro-oxidant activity of flavonoids induces EpRE-mediated gene expression. Chem Res Toxicol, 19(11):1499-1505
42. Maher P, Hanneken A (2008). Regulation of Neural Gene Transcription by Flavonoids. In: Neville V, editor. Polyphenols and Health: New and Recent Advances. New York: Nova Science Publishers, 167-188
43. Rajagopalan S, Rane A, Chinta SJ, Andersen JK (2016). Regulation of ATP13A2 via PHD2-HIF1alpha Signaling Is Critical for Cellular Iron Homeostasis: Implications for Parkinson's Disease. J Neurosci, 36(4):1086-1095
44. Dehay B, Ramirez A, Martinez-Vicente M, Perier C, Canron MH, Doudnikoff E, et al (2012). Loss of P-type ATPase ATP13A2/PARK9 function induces general lysosomal deficiency and leads to Parkinson disease neurodegeneration. Proc Natl Acad Sci USA, 109(24):9611-9616
45. Chen PC, Vargas MR, Pani AK, Smeyne RJ, Johnson DA, Kan YW, et al (2009). Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson's disease: Critical role for the astrocyte. Proc Natl Acad Sci USA, 106(8):2933-2938
46. Jazwa A, Rojo AI, Innamorato NG, Hesse M, Fernandez-Ruiz J, Cuadrado A (2011). Pharmacological targeting of the transcription factor Nrf2 at the basal ganglia provides disease modifying therapy for experimental parkinsonism. Antiox Redox Signal, 14(12):2347-2360
47. Dinkova-Kostova AT, Holtzclaw WD, Wakabayashi N (2005). Keap1, the sensor for electrophiles and oxidants that regulates the phase 2 response, is a zinc metalloprotein. Biochemistry, 44(18):6889-6899
48. Aras AB, Guven M, Akman T, Ozkan A, Sen HM, Duz U, et al (2015). Neuroprotective effects of daidzein on focal cerebral ischemia injury in rats. Neural Regen Res, 10(1):146-152
49. Stout JM, Knapp AN, Banz WJ, Wallace DG, Cheatwood JL (2013). Subcutaneous daidzein administration enhances recovery of skilled ladder rung walking performance following stroke in rats. Behav Brain Res, 256:428-431
50. Chiruta C, Schubert D, Dargusch R, Maher P (2012). Chemical modification of the multitarget neuroprotective compound fisetin. J Med Chem, 55(1):378-389
51. Karuppagounder SS, Madathil SK, Pandey M, Haobam R, Rajamma U, Mohanakumar KP (2013). Quercetin up-regulates mitochondrial complex-I activity to protect against programmed cell death in rotenone model of Parkinson's disease in rats. Neuroscience, 236:136-148